Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232191 · ClinicalTrials.gov registry record · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
A Phase 2 study of Asplenia, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT02232191: Recruiting Phase 2 study of Asplenia, sponsored by University of California, Davis.
NCT02232191 is a Phase 2 study of Asplenia that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02232191, a Phase 2 study of Asplenia, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
Primary Outcome
measured by opsonophagocytosis assay
Conditions Studied
Interventions
- BIOLOGICAL Pneumovax-23
Study Locations (1)
California
- University of California, Davis Medical Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-12 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT02232191 shows while recruiting
NCT02232191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Asplenia appearing as the primary indexed condition, and to 1 intervention - of which Pneumovax-23 is the first listed.
NCT02232191 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02232191 about?
NCT02232191 is a clinical study titled "Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients". Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen cur...
What is the current status of trial NCT02232191?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-12. Estimated completion is 2026-07.
What conditions does trial NCT02232191 study?
This clinical trial studies the following conditions: Asplenia.
What interventions are being tested in trial NCT02232191?
The interventions under investigation include: Pneumovax-23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02232191?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02232191 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02232191's enrollment target sits among peer trials
75 900th of 2000 higher than 1,082 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
- NCT03128034 · 75 participants · Phase 1
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia